脊髓小脑动症和肌缩性侧面硬化之间罕见的关联:一个案例系列
Valerio Ferrari1, Matteo Conti1, Roberta Bovenzi1
1Parkinson Centre, Department of Systems Medicine, University of Rome "Tor Vergata,", Rome, Italy.
概括
脊髓小脑动症2型 (SCA2) 可能会增加患有肌缩侧面硬化症 (ALS) 的风险. 特定的ATXN2基因CAG重复长度会影响这种风险,因此需要进一步研究底层机制.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 神经学 神经学
背景情况:
- 脊髓小脑动症2型 (SCA2) 是一种神经退行性疾病.
- 肌缩侧面硬化症 (ALS) 是一种渐进的运动神经元疾病.
- SCA2与ALS之间的关联需要进一步阐明.
研究的目的:
- 报告一个新的病例,将SCA2与ALS联系起来.
- 探索ATXN2基因CAG重复扩张在ALS风险中的潜在作用.
- 为了研究关联SCA2和ALS的潜在分子机制.
主要方法:
- 一个58岁的男性被诊断出患有SCA2.2的病例报告.
- 电生理学研究包括电肌学,电神经学和运动唤起的潜能.
- 基于经过修订的埃尔埃斯科里亚尔标准 (2015年) 的ALS诊断.
主要成果:
- 患者出现了消化不良和严重的运动障碍,进展到轮椅依赖.
- 电生理学发现与上部和下部运动神经元参与一致.
- 这一案例凸显了SCA2和ALS发展之间的潜在联系.
结论:
- SCA2可能是发展ALS的重要危险因素.
- 在ATXN2基因中特定的CAG重复计数似乎调节了ALS风险.
- 需要进一步的研究来阐明连接SCA2和ALS的生理病理机制.
相关概念视频
Cross-bridge Cycle
117.4K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
117.4K
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541


